Neuer Markt Drives German Shopping Spree
Capitalizing on their hefty valuations, German public biotechs are going on a shopping spree, swapping stock for other companies and thereby creating broader platforms of technologies and in some cases clinical pipelines. In their zest for turning their paper into harder industrial assets, German biotechs are showing themselves far more aggressive than the majority of their American and British counterparts.
You may also be interested in...
Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.
Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.